Medication Review: SLE & Lupus Nephritis: Biologic MOAs Explained

September 2026

In this educational Medication Review, Jennifer Mylod, DNP, provides an overview of the biologic and targeted therapies currently available for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). This video reviews the different mechanisms of action used to target key immune pathways involved in lupus and highlights how these therapies help manage disease activity and improve patient outcomes.

Learn how currently available treatments work by targeting B cells, B-cell activating factor (BAFF/BLyS), type I interferon signaling, and other immune pathways that contribute to inflammation and autoantibody production. Jennifer discusses important therapies used in the management of SLE and lupus nephritis, including belimumab, anifrolumab, rituximab, obinutuzumab, and voclosporin, and explains how their mechanisms differ.

The discussion also explores the evolving treatment landscape for lupus, emphasizing the growing number of therapeutic options available to help reduce disease activity, preserve organ function, and support long-term disease control. Understanding these mechanisms can help clinicians make informed treatment decisions and optimize care for patients with SLE and lupus nephritis.